



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CORGE 000GENAPPLICATION NO
09:875.305

SHEET 1 OF 1

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Dzau et alFILING DATE
June 5, 2001GROUP
1632 / 6 SC

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

1.	Sen and Baltimore, "Inducibility of K Immunoglobulin Enhancer-Binding Protein NF-Kb BY A Posttranslational Mechanism" <u>Cell</u> 47:921-928 (1986)
2.	Ruben et al., "Isolation of a rel-Related Human cDNA That Potentially Encodes THE 65-kD Subunit of NF-kB" <u>Science</u> 251:1490-1493 (1991)
3.	Hiscott, J. Marois, J. et al., "Characterization of a Functional NF-kB Site in the Human Interleukin 1 β Promoter: Evidence for a Positive Autoregulatory Loop" <u>Mol. Cell Biol.</u> 13:6231-40 (1993)
4.	Kunsch and Rosen, "NF-Kb Subunit-Specific regulation of the Interleukin-8 Promoter" <u>Mol. Cell. Biol.</u> 13(10):6:6137-6146 (1993)
5.	Shimizu et al., "Involvement of a NF-kB-Like Transcription Factor in the Activation of the Interleukin-6 Gene by Inflammatory Lymphokines", <u>Mol. Cell. Biol.</u> 10(2):561-568 (1990)
6.	Libermann and Baltimore, "Activation of Interleukin-6 Gene Expression through the NF-kB Transcription Factor" <u>Mol. Cell. Biol.</u> 10:2327-2334 (1990)
7.	Zhang et al., "Interleukin-6 Induction by Tumor Necrosis Factor and Interleukin-1 in Human Fibroblasts Involves Activation of a Nuclear Factor Binding to a kB-Like Sequence" <u>Mol. Cell. Biol.</u> 10:3818-3823 (1990)
8.	Mann et al., "Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised controlled trial" <u>Lancet</u> 354:1493-1498 (1999)
9.	Quan et al., "Administration of NF-kB decoy inhibits pancreatic activation of NF-kB and prevents diabetogenesis by alloxan in mice" <u>FASEB</u> 15:1616-1618 (2001)

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED. WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.